• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

Message on the passing of Sir Nicholas White from DNDi Board Chair Dr Marie-Paule Kieny and DNDi Executive Director Dr Luis Pizarro

2 Feb 2026

We are deeply saddened to learn of the passing of Sir Nicholas White, a towering leader in medical science and global health and a cherished member of our community. Nick was a trusted advisor, generous mentor, passionate advocate for DNDi’s mission, and tireless champion of the communities we serve.

Over decades of commitment to scientific excellence, Nick advanced groundbreaking research and world-class science – for neglected diseases and for marginalized communities that benefit least from scientific progress.

From 2016 to 2025, Nick served as Chair of DNDi’s Scientific Advisory Committee, embracing the role with extraordinary dedication over a decade of tenure. He helped steer the scientific direction of our R&D portfolio, challenged us to be ambitious and rigorous, and helped ensure that the highest scientific standards remained central to our mission and day-to-day decision-making.

Nick’s scientific contributions reshaped the treatment of infectious diseases and saved countless lives. His role in the development and global adoption of artemisinin-based combination therapies for malaria transformed the treatment landscape for the disease and dramatically reduced mortality across endemic regions. His work on the clinical management of severe malaria set enduring standards that still guide practice today.

Working with Nick was a privilege. With his exceptionally sharp intellect and quick English wit, Nick challenged assumptions, advised with candour, and helped our teams to navigate difficult scientific and operational terrain. We are profoundly grateful for the wisdom, integrity, and humanity he brought to DNDi and our mission.

Nick’s legacy will endure through the patients whose lives he improved, the scientists he inspired, and the institutions he shaped to advance science driven by public health need. He will be deeply missed, but we take comfort in the certainty that Nick’s wisdom and dedication will continue to guide and inspire our work. On behalf of DNDi, we extend our heartfelt condolences to Nick’s family, friends, and colleagues around the world.

Read, watch, share

Loading...
News
30 Jan 2026

Imperial and DNDi strengthen partnership to accelerate treatments for neglected diseases 

From risk to remedy: Fast-tracking the end of sleeping sickness
Videos
28 Jan 2026

From risk to remedy: Fast-tracking the end of sleeping sickness

Dr Joseph Gichuru, Deputy Executive Director and the Director of Operations, APHRC, and Prof. Samuel Kariuki, Continental Lead Africa and Eastern Africa Director, DNDi
News
27 Jan 2026

DNDi and APHRC sign MoU to forge strategic alliance to bridge research and capacity enhancement gaps

Statements
23 Jan 2026

DNDi’s briefing note for 158th Session of the WHO Executive Board

News
16 Dec 2025

DNDi 2025 in Review

News
8 Dec 2025

DNDi statement on COP30: Advancing health in the climate agenda

News
4 Dec 2025

Dr Javid Abdelmoneim, Datuk Dr Mahathar bin Abd Wahab, Dr Taruna Madan, Violet Naanyu, and Dr Mario Santos Moreira join the Board of Directors at DNDi

Press releases
27 Nov 2025

International seminar explores the development of treatments for dengue for populations not covered by vaccines

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license